What is claimed is:

1. A compound of formula (I):



(I)

wherein

each of x and y is, independently of the other, 0 or 1;

$R_1$ is an organic moiety that can be bound to nitrogen;

X is C=O (especially preferred) or C=S with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is ($CR_7$), wherein $R_7$ is hydrogen or an organic or inorganic moiety with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero or y is 1 and then -R is $\rightarrow$O; and

each of $R_2$, $R_3$, $R_4$, $R_5$ and $R_6$, independently of the others, is an organic moiety or hydrogen or an inorganic moiety, with the proviso that $R_3$ cannot be unsubstituted phenyl unless $R_1$ is phenyl substituted with a heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1,

wherein

each of x and y is, independently of the other, 0 or 1;

$R_1$ is substituted or unsubstituted aryl or heteroaryl, especially phenyl, which is substituted with up to 4 substituents, preferably up to 3 substituents, where the substituents are the same or different and are independently selected from halo, e.g., F or Cl; $C_1$-$C_7$lower alkyl which may be unsubstituted or substituted with halo,

especially methyl, ethyl, propyl or trifluoromethyl; cyano; cyano-lower alkyl, e.g., cyanomethyl, cyanoethyl or cyanopropyl; lower alkoxy; amino; amino-lower alkyl; amino-lower alkoxy; amino-lower alkyl sulfanyl; or thiol-lower alkyl, wherein the amino group can be mono- or di-substituted, e.g., $-(C_1-C_7)_mNR_8R_9$ or $-O-(C_1-C_7)_mNR_8R_9$,

wherein

m is 0 or 1; and

$R_8$ and $R_9$ can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or

$R_8$ and $R_9$, together with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., azetidinyl, pyrrolidinyl, piperidino, morpholinyl, imidazolinyl, imidazolinyl-ethyl, piperazinyl or lower alkyl-piperazinyl; amino-carbonyl-lower alkyl, e.g., $R_8R_9$-N-C(O)-$CH_2$-, wherein $R_8$ and $R_9$ are as defined above; heterocyclyl; heterocyclyl-lower alkyl; heterocyclyl-lower alkoxy; or heterocyclyl-lower alkanesulfanyl, wherein the heterocyclyl is a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolyl, imidazolinyl, pyrrolidinyl, morpholinyl, azetidinyl, pyridyl, piperidino, piperidyl, piperazinyl or lower alkyl-piperazinyl; substituted or unsubstituted amide; amide-lower alkyl, e.g., $-CH_2-CH(NH_2)-C(O)-NH_2$), wherein alkyl may be linear or cyclic, e.g., cyclopropylene; and the alkyl in any of the substituents above may optionally be substituted with $-NR_8R_9$, wherein $R_8$ and $R_9$ are as defined above;

X is C=O or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is ($CR_7$), wherein $R_7$ is hydrogen or an organic moiety, such as $C_1$-$C_7$lower alkyl; amino; or amino alkyl, wherein the alkyl may be unsubstituted or substituted with halo, e.g., methyl, ethyl, propyl or trifluoromethyl; lower alkoxy, e.g., methoxy; or cycloalkyl, e.g., cyclopropyl; with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond; and with the proviso that then y is zero, or y is 1 and then -R is $\rightarrow$O;

$R_2$ is hydrogen;

$R_3$ is unsubstituted or substituted $C_5$-$C_{14}$heterocyclyl, e.g., thienyl, benzo[1,3]dioxolo, indolyl, benzofuranyl or pyridiyl; unsubstituted or substituted $C_5$-$C_{14}$aryl, e.g., phenyl or phenyl substituted with up to 4 substituents, preferably up to 3 substituents, which are the same or different and are selected from halo, e.g., Cl or F; hydroxy; $C_1$-$C_4$lower alkoxy, e.g., methoxy; lower alkyl, e.g., methyl; or $-(C_1-C_4)_mNR_8R_9$,

wherein

m is 0 or 1; and

$R_8$ and $R_9$, are as defined above, e.g., piperazinyl, methylpiperazinyl, morpholinyl or pyrrolidinyl;

$R_4$ is hydrogen or halo, e.g., fluoro or chloro;

$R_5$ is hydrogen; and

$R_6$ is hydrogen, amino, amino alkyl or alkylamido, e.g., methylamido -NHC(O)-$CH_3$), with the proviso that $R_3$ cannot be unsubstituted phenyl unless $R_1$ is phenyl substituted with an heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

3. A compound according to Claim 1,

wherein

each of x and y is, independently of the other, 0 or 1;

$R_1$ is substituted or unsubstituted phenyl where the phenyl is substituted with up to 4 substituents, preferably up to 3 substituents, where the substituents are the same or different and are independently selected from halo, e.g., F or Cl; $C_1$-$C_7$lower alkyl, which may be unsubstituted or substituted with halo, especially methyl, ethyl, propyl or trifluoromethyl; cyano; cyano-lower alkyl, e.g., cyanomethyl, cyanoethyl or cyanopropyl; amino; amino-lower alkyl, wherein the amino group can be mono- or di-substituted, e.g., $-(C_1-C_7)_mNR_8R_9$ or $-O-(C_1-C_7)_mNR_8R_9$,

wherein

m is 0 or 1; and

$R_8$ and $R_9$ can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or

$R_8$ and $R_9$, together with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolinyl, imidazolinyl-ethyl, piperazinyl or lower alkyl-piperazinyl; amino-carbonyl-lower alkyl, e.g.,

$R_8R_9$-N-C(O)-$CH_2$-, wherein $R_8$ and $R_9$ are as defined above; heterocyclyl; heterocyclyl-lower alkyl; heterocyclyl-lower alkoxy; or heterocyclyl-lower alkanesulfanyl, wherein the heterocyclyl is a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolinyl, imidazolinyl, imidazolinyl-ethyl, piperazinyl or lower alkyl-piperazinyl; substituted or unsubstituted amide; amide-lower alkyl, e.g., -$CH_2$-CH($NH_2$)-C(O)-$NH_2$, wherein alkyl may be linear or cyclic, e.g., cyclopropylene; and the alkyl in any of the substituents above may optionally be substituted with -$NR_8R_9$, wherein $R_8$ and $R_9$ are as defined above;

X is ($CR_7$), wherein $R_7$ is hydrogen; lower alkyl, e.g., methyl or ethyl; amino; or amino alkyl, with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero, or y is 1 and then -R is $\rightarrow$O;

$R_2$ is hydrogen;

$R_3$ is unsubstituted or substituted $C_5$-$C_{14}$heterocyclyl, e.g., thienyl, benzo[1,3]dioxolo, indolyl, benzofuranyl or pyridiyl; unsubstituted or substituted $C_5$-$C_{14}$aryl, e.g., phenyl or phenyl substituted with up to 4 substituents, preferably up to 3 substituents, which are the same or different and are selected from halo, e.g., Cl or F; hydroxy; $C_1$-$C_4$lower alkoxy, e.g., methoxy; lower alkyl, e.g., methyl; or -($C_1$-$C_4$)$_m$$NR_8R_9$, wherein

m is 0 or 1; and

$R_8$ and $R_9$ are as defined above, e.g., piperazinyl, methylpiperazinyl, morpholinyl or pyrrolidinyl;

$R_4$ is hydrogen or halo, (e.g. fluoro or chloro);

$R_5$ is hydrogen; and

$R_6$ is hydrogen, with the proviso that $R_3$ cannot be unsubstituted phenyl unless $R_1$ is phenyl substituted with an heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound of formula (I), according to any of Claims 1-3, or a pharmaceutically acceptable salt thereor, and a pharmaceutically acceptable carrier.

5. A compound of the formula (I), according to any one of Claims 1-3, for use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease.

6. A compound according to Claim 5, wherein the protein kinase dependent disease is preferably one depending on PKB, ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) PKB, ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the PKB, ALK, S6K1 or RET pathways, or a disease dependent on any two or more of the kinases just mentioned.

7. Use of a compound of formula (I), according to any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, in the treatment of a protein kinase dependent disease.

8. Use of a compound of formula (I), according to any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for use in the treatment of a protein kinase dependent disease.

9. The use according to Claims 7 and 8, wherein the protein kinase dependent disease is preferably one depending on PKB, ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) PKB, ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the PKB, ALK, S6K1 or RET pathways, or a disease dependent on any two or more of the kinases just mentioned.

10. A method of treatment of a disease that responds to inhibition of a protein kinase, which comprises administering a prophylactically or especially therapeutically effective amount of a compound of formula (I) according to any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, to a warm-blooded animal, e.g., a human, in need of such treatment.

11. A method according to Claim 10, wherein the disease to be treated is a proliferative disease, preferably a benign or especially malignant tumor, more preferably carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, thyroid, sarcoma, glioblastomas, multiple myeloma, gastrointestinal cancer, colon carcinoma, colorectal adenoma, tumor of the neck and head,

an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, especially of epithelial character, mammary carcinoma, leukemia, metabolic diseases, type II diabetes, obesity, hyperlipidemia and atherosclerosis.

12. A compound according to formula (I), for use in the treatment of a protein kinase dependent disease, especially one depending on ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the ALK, S6K1 or RET pathways or disease comprising administering a compound according to formula (I)



(I)

,

wherein

each of x and y is, independently of the other, 0 or 1;

$R_1$ is an organic moiety that can be bound to nitrogen;

X is C=O, especially preferred or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is ($CR_7$), wherein $R_7$ is hydrogen or an organic or inorganic moiety with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero or y is 1 and then -R is $\rightarrow$O; and

each of $R_2$, $R_3$, $R_4$, $R_5$ and $R_6$, independently of the others, is an organic moiety or hydrogen or an inorganic moiety;

or a pharmaceutically acceptable salt thereof.

13. A compound according to Claim 12, comprising a the compound of the formula (I), or a pharmaceutically acceptable salt thereof,

wherein

each of x and y is, independently of the other, 0 or 1;

$R_1$ is phenyl or phenyl-lower alkyl, each of which, in the phenyl moiety, is unsubstituted or substituted by up to three moieties independently selected from halogen, especially fluoro, chloro, bromo or iodo; lower alkyl, especially methyl or ethyl; halo-lower alkyl, especially trifluoromethyl; hydroxy; lower alkoxy, especially methoxy; $C_6$-$C_{14}$aryl, especially phenyl; hydroxy-lower alkyl, especially 2-hydroxyethyl or hydroxymethyl; amino; amino-lower alkyl, especially aminomethyl or 2-aminoethyl; amidino; *N*-hydroxy-amidino; amidino-lower alkyl, such as 2-amidinoethyl; *N*-hydroxyamidino-lower alkyl, especially *N*-hydroxy-amidino-methyl or -2-ethyl; cyano-lower alkyl, especially cyanomethyl; and cyano or is $C_3$-$C_8$cycloalkyl, especially cyclohexyl; or hydroxy$C_3$-$C_8$cycloalkyl, especially hydroxy-cyclohexyl;

X is C=O or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond, and with the proviso that then y is 1 and R is hydrogen; lower alkyl, especially methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, 2,2-dimethylpropyl or 2-ethyl-*n*-butyl; mono- or di-hydroxy-lower alkyl, especially 2,3-dihydroxy-propyl or 3-hydroxy-2,2-dimethylpropyl; $C_6$-$C_{14}$aryl, which is unsubstituted or substituted by 1-3 substituents selected from lower alkyl, especially methyl or ethyl; halo-lower alkyl, especially trifluoromethyl; halogen, especially chloro; amino; lower alkanoylamino; lower alkoxy, especially methoxy and nitro; $C_3$-$C_8$cycloalkyl, especially cyclopropylmethyl or cyclohexylmethyl; or furanyl-lower alkyl, especially 3-furanyl-methyl, or

X is ($CR_7$), wherein $R_7$ is hydrogen or an organic or inorganic moiety that can be bound to nitrogen with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero, or y is 1 and then -R is $\rightarrow$O;

$R_2$ is hydrogen;

$R_3$ is hydrogen; lower alkyl, especially ethyl; halo, especially fluoro, chloro or bromo; lower alkoxy, especially methoxy; or unsubstituted or substituted $C_6$-$C_{14}$aryl, especially phenyl, hydroxyphenyl or methoxyphenyl;

$R_4$ is hydrogen or halo, especially chloro;

$R_5$ is hydrogen or lower alkoxy, especially *n*-lower hexyloxy; and

$R_6$ is hydrogen, halo, especially chloro; $C_6$-$C_{14}$aryl, especially phenyl; $C_3$-$C_8$cycloalkyl, especially cyclopropyl; amino; lower alkyl-amino, especially methylamino or *n*-butylamino; hydroxy-lower alkylamino, especially 2-hydroxyethyl-amino; or $C_6$-$C_{14}$arylcarbonylamino, especially benzoylamino.

14. Use of a compound of formula (I), according to Claim 12 or 13, for use in the preparation of a pharmaceutical composition for the treatment of a protein kinase dependent disease, especially one depending on ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the ALK, S6K1 or RET pathways or disease.

15. A compound according to Claim 1, selected from the group consisting of:

[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

2-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

(4-Amino-3-chloro-phenyl)-acetonitrile;

{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;

[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;

2-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;

2-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

[2-Fluoro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-2-fluoro-phenyl]-acetonitrile;

{2-Fluoro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;

2-[2-Fluoro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-2-fluoro-phenyl]-ethylamine;

2-{2-Fluoro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;

[3-Methyl-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

{4-[8-(1*H*-Indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-3-methyl-phenyl}-acetonitrile;

2-[3-Methyl-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-{4-[8-(1*H*-Indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-3-methyl-phenyl}-ethylamine;

(*R*)-2-Amino-3-[4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionamide;

(*R*)-2-Amino-3-[4-(8-benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionamide;

[3,5-Dichloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[3,5-Dichloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

2-[3,5-Dichloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[3,5-Dichloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

{4-[8-(4-Hydroxy-phenyl)-imidazo[4,5-*c*]quinolin-1-yl]-3-trifluoromethyl-phenyl}-acetonitrile;

4-{1-[4-(2-Amino-ethyl)-2-trifluoromethyl-phenyl]-1*H*-imidazo[4,5-*c*]quinolin-8-yl}-phenol;

3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-3-chloro-phenyl]-propionitrile;

3-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;

3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-3-chloro-phenyl]-propylamine;

3-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;

8-Benzo[1,3]dioxol-5-yl-1-{4-[2-(4,5-dihydro-1*H*-imidazol-2-yl)-ethyl]-phenyl}-1*H*-imidazo[4,5-*c*]quinoline;

[3-Chloro-4-(2-methyl-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[3-Chloro-4-(2-methyl-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

2-[3-Chloro-4-(2-methyl-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[3-Chloro-4-(2-methyl-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;

[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

2-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;

2-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

3-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;

3-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;

[3-Chloro-4-(7-fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[3-Chloro-4-(7-fluoro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;

{3-Chloro-4-[7-fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;

2-[3-Chloro-4-(7-fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[3-Chloro-4-(7-fluoro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;

2-{3-Chloro-4-[7-fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;

[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(7-Chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;

[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

2-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(7-Chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;

2-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

3-[4-(8-Benzo[1,3]dioxol-5-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;

3-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzo[1,3]dioxol-5-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;

3-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;

2-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

2-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;

3-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-{3-Chloro-4-[7-chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;

3-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-{3-Chloro-4-[7-chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;

3-[4-(2-Amino-7-chloro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(2-Amino-8-bromo-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(3-Amino-6-bromo-7-chloro-quinolin-4-ylamino)-phenyl]-propionitrile;

3-[4-(2-Amino-8-benzofuran-2-yl-7-chloro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

1-[4-(3-Amino-propyl)-phenyl]-7-chloro-8-thiophen-3-yl-1*H*-imidazo[4,5-*c*]quinolin-2-ylamine;

1-[4-(3-Amino-propyl)-phenyl]-8-benzofuran-2-yl-7-chloro-1*H*-imidazo[4,5-*c*]quinolin-2-ylamine;

8-(2,4-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

8-(2,5-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

8-(3,4-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-(3,4,5-trimethoxy-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

8-(2,3-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-(2,3,4-trimethoxy-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-pyridin-4-yl-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-pyridin-3-yl-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-(3-methoxy-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

{3-[1-(2-Fluoro-phenyl)-1*H*-imidazo[4,5-*c*]quinolin-8-yl]-benzyl}-dimethyl-amine;

1-(2-Fluoro-phenyl)-8-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-(3-morpholin-4-ylmethyl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-(3-piperazin-1-ylmethyl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

1-(2-Fluoro-phenyl)-8-(3-pyrrolidin-1-ylmethyl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

1-Phenyl-8-(3-piperazin-1-yl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;

8-(3-Fluoro-phenyl)-1-phenyl-1*H*-imidazo[4,5-*c*]quinoline;

8-[3-(4-Methyl-piperazin-1-yl)-phenyl]-1-phenyl-1*H*-imidazo[4,5-*c*]quinoline;

4-{1-[4-(4-Methyl-piperazin-1-yl)-phenyl]-1*H*-imidazo[4,5-*c*]quinolin-8-yl}-phenol;

1-[4-(4-Methyl-piperazin-1-yl)-phenyl]-8-phenyl-1*H*-imidazo[4,5-*c*]quinoline; and

[4-(8-Pyridin-4-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile.

# INTERNATIONAL SEARCH REPORT

Int[illegible]al Application No
PCT/EP2004/013178

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D471/04 A61K31/435 A61P35/00
//(C07D471/04,235:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| A | WO 02/46188 A (3M INNOVATIVE PROPERTIES COMPANY; CROOKS, STEPHEN L; GRIESGRABER, GEOR) 13 June 2002 (2002-06-13) the whole document | 1-15 |
| A | US 5 605 899 A (GERSTER JOHN F 'US! ET AL) 25 February 1997 (1997-02-25) the whole document | 1-15 |
| A | US 6 331 539 B1 (CROOKS STEPHEN L ET AL) 18 December 2001 (2001-12-18) the whole document | 1-15 |
| A | EP 1 256 582 A (HOKURIKU SEIYAKU CO., LTD) 13 November 2002 (2002-11-13) the whole document | 1-15 |

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 7 March 2005 | 16/03/2005 |

| Name and mailing address of the ISA | Authorized officer |
|---|---|
| European Patent Office, P.B. 5818 Patentlaan 2<br>NL – 2280 HV Rijswijk<br>Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,<br>Fax: (+31–70) 340–3016 | Fritz, M |

Form PCT/ISA/210 (second sheet) (January 2004)

# INTERNATIONAL SEARCH REPORT

Int nal Application No
PCT/EP2004/013178

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| A | EP 1 104 764 A (HOKURIKU SEIYAKU CO., LTD)<br>6 June 2001 (2001-06-06)<br>the whole document | 1-15 |
| A | EP 0 389 302 A (RIKER LABORATORIES, INC)<br>26 September 1990 (1990-09-26)<br>the whole document | 1-15 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte nal Application No
PCT/EP2004/013178

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---|---|---|
| WO 0246188 A | 13-06-2002 | AU 3061802 A | 18-06-2002 |
| | | AU 3248202 A | 18-06-2002 |
| | | AU 3249702 A | 18-06-2002 |
| | | AU 3951602 A | 18-06-2002 |
| | | AU 3951702 A | 18-06-2002 |
| | | AU 3953002 A | 18-06-2002 |
| | | BR 0116026 A | 21-12-2004 |
| | | BR 0116047 A | 30-09-2003 |
| | | CA 2430844 A1 | 13-06-2002 |
| | | CA 2431151 A1 | 13-06-2002 |
| | | CA 2436846 A1 | 13-06-2002 |
| | | CA 2436980 A1 | 13-06-2002 |
| | | CA 2436983 A1 | 13-06-2002 |
| | | CA 2436984 A1 | 13-06-2002 |
| | | CN 1479738 A | 03-03-2004 |
| | | CN 1487939 A | 07-04-2004 |
| | | CN 1479739 A | 03-03-2004 |
| | | CZ 20031560 A3 | 12-05-2004 |
| | | CZ 20031561 A3 | 14-04-2004 |
| | | CZ 20031562 A3 | 17-03-2004 |
| | | CZ 20031563 A3 | 18-02-2004 |
| | | CZ 20031591 A3 | 12-11-2003 |
| | | CZ 20031592 A3 | 14-01-2004 |
| | | EE 200300268 A | 15-10-2003 |
| | | EE 200300270 A | 15-10-2003 |
| | | EE 200300271 A | 15-10-2003 |
| | | EE 200300272 A | 15-10-2003 |
| | | EE 200300274 A | 15-10-2003 |
| | | EE 200300275 A | 15-10-2003 |
| | | EP 1341789 A2 | 10-09-2003 |
| | | EP 1341790 A2 | 10-09-2003 |
| | | EP 1341791 A2 | 10-09-2003 |
| | | EP 1339715 A2 | 03-09-2003 |
| | | EP 1341792 A2 | 10-09-2003 |
| | | EP 1343784 A2 | 17-09-2003 |
| | | HR 20030461 A2 | 30-06-2004 |
| | | HR 20030462 A2 | 30-04-2004 |
| | | HR 20030463 A2 | 30-04-2004 |
| | | HR 20030464 A2 | 30-06-2004 |
| | | HR 20030466 A2 | 30-06-2004 |
| | | HR 20030467 A2 | 30-04-2004 |
| | | HU 0400704 A2 | 28-06-2004 |
| | | HU 0400710 A2 | 28-06-2004 |
| | | JP 2004532810 T | 28-10-2004 |
| US 5605899 A | 25-02-1997 | US 5389640 A | 14-02-1995 |
| | | US 5977366 A | 02-11-1999 |
| | | US 2003119861 A1 | 26-06-2003 |
| | | US 6348462 B1 | 19-02-2002 |
| | | US 2003212270 A1 | 13-11-2003 |
| | | US 2004122231 A1 | 24-06-2004 |
| | | US 5741909 A | 21-04-1998 |
| | | US 2002115861 A1 | 22-08-2002 |
| | | AT 179711 T | 15-05-1999 |
| | | AT 229943 T | 15-01-2003 |
| | | AU 658621 B2 | 27-04-1995 |
| | | AU 1566992 A | 06-10-1992 |
| | | AU 673309 B2 | 31-10-1996 |

# INTERNATIONAL SEARCH REPORT

information on patent family members

Int[illegible]al Application No
PCT/EP2004/013178

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---|---|---|
| US 5605899 A | | AU 2715795 A | 21-09-1995 |
| | | CA 2104782 A1 | 02-09-1992 |
| | | CA 2289219 A1 | 02-09-1992 |
| | | CZ 9301788 A3 | 18-10-1995 |
| | | DE 69229114 D1 | 10-06-1999 |
| | | DE 69229114 T2 | 04-11-1999 |
| | | DE 69232878 D1 | 30-01-2003 |
| | | DE 69232878 T2 | 20-11-2003 |
| | | DK 582581 T3 | 08-11-1999 |
| | | DK 872478 T3 | 31-03-2003 |
| | | EP 0582581 A1 | 16-02-1994 |
| | | EP 0872478 A2 | 21-10-1998 |
| | | ES 2131070 T3 | 16-07-1999 |
| | | ES 2186034 T3 | 01-05-2003 |
| | | HU 67026 A2 | 30-01-1995 |
| | | HU 211242 B3 | 28-11-1995 |
| | | HU 220667 B1 | 29-04-2002 |
| | | HU 222247 B1 | 28-05-2003 |
| | | HU 222251 B1 | 28-05-2003 |
| | | HU 222250 B1 | 28-05-2003 |
| | | IE 920605 A1 | 09-09-1992 |
| | | IE 990988 A1 | 13-12-2000 |
| | | IL 101110 A | 08-12-1995 |
| | | IL 114570 A | 31-10-1996 |
| | | JP 2955019 B2 | 04-10-1999 |
| | | JP 6504789 T | 02-06-1994 |
| | | KR 235389 B1 | 15-12-1999 |
| | | NO 933069 A | 01-11-1993 |
| | | NZ 241784 A | 27-06-1995 |
| | | PH 31614 A | 12-01-1999 |
| | | SG 46492 A1 | 20-02-1998 |
| | | SG 70625 A1 | 22-02-2000 |
| | | WO 9215582 A1 | 17-09-1992 |
| | | ZA 9201540 A | 25-11-1992 |
| US 6331539 B1 | 18-12-2001 | AU 772179 B2 | 08-04-2004 |
| | | AU 5328400 A | 02-01-2001 |
| | | BR 0011433 A | 05-03-2002 |
| | | CA 2376305 A1 | 21-12-2000 |
| | | CN 1354663 A | 19-06-2002 |
| | | CZ 20014363 A3 | 13-03-2002 |
| | | EE 200100669 A | 17-02-2003 |
| | | EP 1198233 A1 | 24-04-2002 |
| | | HR 20010890 A1 | 31-08-2003 |
| | | HU 0201431 A2 | 28-08-2002 |
| | | JP 2003501474 T | 14-01-2003 |
| | | MX PA01012547 A | 14-10-2003 |
| | | NO 20015502 A | 07-02-2002 |
| | | NZ 515967 A | 31-10-2003 |
| | | PL 352554 A1 | 25-08-2003 |
| | | SK 17922001 A3 | 04-04-2002 |
| | | TR 200103575 T2 | 21-06-2002 |
| | | WO 0076519 A1 | 21-12-2000 |
| | | US 2004029877 A1 | 12-02-2004 |
| | | US 2003130299 A1 | 10-07-2003 |
| | | US 2004204438 A1 | 14-10-2004 |
| | | AU 766565 B2 | 16-10-2003 |
| | | AU 5328100 A | 02-01-2001 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte nal Application No
PCT/EP2004/013178

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---|---|---|
| US 6331539 B1 | | AU 773113 B2 | 20-05-2004 |
| | | AU 6334900 A | 02-01-2001 |
| | | BR 0011448 A | 14-12-2004 |
| | | BR 0014214 A | 08-09-2004 |
| | | CA 2376296 A1 | 21-12-2000 |
| | | CA 2376304 A1 | 21-12-2000 |
| | | CN 1353609 A | 12-06-2002 |
| | | CN 1355701 A | 26-06-2002 |
| | | CZ 20014364 A3 | 13-03-2002 |
| | | EE 200100668 A | 17-02-2003 |
| | | EE 200100670 A | 17-02-2003 |
| | | EP 1198232 A1 | 24-04-2002 |
| | | EP 1187613 A1 | 20-03-2002 |
| | | EP 1438958 A1 | 21-07-2004 |
| | | HR 20010888 A1 | 31-08-2003 |
| | | HR 20010889 A1 | 31-08-2003 |
| | | HU 0201664 A2 | 28-08-2002 |
| | | HU 0202254 A2 | 28-10-2002 |
| | | JP 2003501466 T | 14-01-2003 |
| | | JP 2003501473 T | 14-01-2003 |
| | | MX PA01012508 A | 02-07-2002 |
| | | NO 20015503 A | 08-02-2002 |
| | | NO 20015504 A | 07-02-2002 |
| EP 1256582 A | 13-11-2002 | AU 3058401 A | 20-08-2001 |
| | | BG 107067 A | 30-09-2003 |
| | | BR 0108303 A | 05-03-2003 |
| | | CA 2399136 A1 | 16-08-2001 |
| | | EP 1256582 A1 | 13-11-2002 |
| | | HU 0204474 A2 | 28-04-2003 |
| | | MX PA02007525 A | 13-12-2002 |
| | | NO 20023750 A | 07-10-2002 |
| | | SK 11202002 A3 | 04-03-2003 |
| | | US 2004054182 A1 | 18-03-2004 |
| | | CN 1422269 A | 04-06-2003 |
| | | CZ 20022626 A3 | 12-02-2003 |
| | | WO 0158900 A1 | 16-08-2001 |
| | | JP 2002161095 A | 04-06-2002 |
| | | PL 355866 A1 | 31-05-2004 |
| | | ZA 200206698 A | 21-08-2003 |
| EP 1104764 A | 06-06-2001 | JP 2000119271 A | 25-04-2000 |
| | | AU 744388 B2 | 21-02-2002 |
| | | AU 5197499 A | 06-03-2000 |
| | | BG 105271 A | 30-11-2001 |
| | | BR 9914306 A | 21-05-2002 |
| | | CA 2339562 A1 | 24-02-2000 |
| | | EP 1104764 A1 | 06-06-2001 |
| | | HR 20010144 A1 | 30-04-2002 |
| | | HU 0103406 A2 | 28-02-2002 |
| | | NO 20010676 A | 10-04-2001 |
| | | NZ 509939 A | 28-08-2002 |
| | | PL 346155 A1 | 28-01-2002 |
| | | SK 1942001 A3 | 03-12-2001 |
| | | US 6518265 B1 | 11-02-2003 |
| | | CN 1323307 A | 21-11-2001 |
| | | CZ 20010503 A3 | 14-11-2001 |
| | | WO 0009506 A1 | 24-02-2000 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int[illegible]nal Application No
PCT/EP2004/013178

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---|---|---|
| EP 1104764 A | | TR 200100439 T2 | 21-05-2001 |
| | | TW 533209 B | 21-05-2003 |
| | | ZA 200101452 A | 17-09-2001 |
| EP 0389302 A | 26-09-1990 | US 4929624 A | 29-05-1990 |
| | | AU 632099 B2 | 17-12-1992 |
| | | AU 5142690 A | 27-09-1990 |
| | | CA 2012226 A1 | 23-09-1990 |
| | | CS 9103906 A3 | 17-06-1992 |
| | | DE 69011914 D1 | 06-10-1994 |
| | | DE 69011914 T2 | 23-03-1995 |
| | | EP 0389302 A1 | 26-09-1990 |
| | | ES 2060026 T3 | 16-11-1994 |
| | | JP 2942584 B2 | 30-08-1999 |
| | | JP 3027381 A | 05-02-1991 |
| | | KR 180226 B1 | 20-03-1999 |
| | | US 5037986 A | 06-08-1991 |